Clinical trial
Post-Marketing Surveillance(PMS) of Safety and Efficacy of Samsca® Tablets in Korean Patients With ADPKD
NCT03406286 is registered in ClinicalTrials.gov with Korea Otsuka Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-Marketing Surveillance(PMS) of Safety and Efficacy of Samsca® Tablets in Korean Patients With ADPKD
- Lead sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 19, 2016
- Completion date
- December 31, 2024
- Enrollment
- 2,067 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
safety